Relmada Therapeutics (RLMD) Payables (2012 - 2026)

Relmada Therapeutics (RLMD) has reported Payables for 15 consecutive years, with $5.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Payables rose 353.07% year-over-year to $5.7 million; the TTM figure through Mar 2026 stood at $5.7 million (up 353.07% YoY), while the FY2025 annual figure was $1.6 million, down 62.02% from the prior year.
• Payables grew to $5.7 million in Q1 2026 per RLMD's latest filing, from $1.6 million in the prior quarter.
• Across five years, Payables topped out at $10.7 million in Q1 2022 and bottomed at $1.3 million in Q1 2025.
• Historically, Payables has averaged $4.5 million across 5 years, with a median of $4.2 million in 2024.
• Annual changes were most pronounced in 2025 — Payables tumbled 75.62% — and 2026, when it jumped 353.07%.
• Relmada Therapeutics' Payables stood at $5.3 million in 2022, then slumped by 33.37% to $3.5 million in 2023, then advanced by 17.81% to $4.1 million in 2024, then plunged by 62.02% to $1.6 million in 2025, then soared by 265.3% to $5.7 million in 2026.
• Business Quant data shows RLMD's Payables at $5.7 million in Q1 2026, $1.6 million in Q4 2025, and $1.5 million in Q3 2025.